About us
and lives of people
around the world by
applying cutting-edge
science and technology
to medicine.
LTT’s Vision
Contributing to the vitalization
of the life science and industry in Japan.
Contributing to human health
and welfare through
the development of innovative drug.
With a venture spirit,
challenging new things and open up an era.
LTT’s Features:
Bridge to deliver drugs to patients through smart drug discovery (DR, DDS)
There are many ways to develop drugs, but we practice smart drug discovery to create drugs “quickly and economically ” to save patients suffering from diseases as soon as possible. Specifically, we are developing new drugs efficiently using drug repositioning (DR), in which new effects of drugs already in clinical use (approved drugs) are discovered and developed as drugs for other diseases, and drug delivery systems (DDS), in which the delivery of approved drugs in the body is modified to enhance their effects and reduce their side effects. Drug repositioning (DR) and drug delivery systems (DDS) are used to efficiently develop new drugs.
Bridge connecting the healthcare business between China and Japan
Founded more than 25 years ago by our company and a Chinese government hospital, Beijing Tide Pharmaceutical Co., Ltd. has grown to become one of China’s leading pharmaceutical companies. Sino Biopharmaceutical Co., Ltd, which invested in and led the growth of Beijing Tide, is a publicly listed company in Hong Kong and one of China’s top pharmaceutical groups with many pharmaceutical companies under its umbrella. We have formed a capital and business alliance with Sino Biopharmaceutical Ltd. and Beijing Tide Pharmaceutical Co., Ltd., and act as a contact point for both companies in Japan.
Bridge between academia and pharmaceutical companies
Our company is a drug discovery venture originating from St. Marianna University school of Medicine, and both our founder and current CEO have long served as university professors. Therefore, we have a good understanding of both academia and pharmaceutical companies, and we hope to develop epoch-making drugs by connecting the two. For example, we conduct DR joint research with academia and out-license the results to pharmaceutical companies.
LTT’s challenge
Licensing out and marketing of
existing pipeline
Creation of a new pipeline
at the Shonan Research Center
Collaboration with academia
and pharmaceutical companies
Development of China business
and creation of new business
The Company has set the above four goals. As for our existing pipeline, we are accelerating the launch of one Phase III clinical study and two Phase II clinical study at the same time. The Shonan Research Center, located in the Shonan health innovation park, is working day and night to develop groundbreaking new drugs. On the other hand, DR has been actively conducted in academia recently, but its out-licensing to pharmaceutical companies has not been successful. Therefore, we would like to make out-licensing to pharmaceutical companies possible through our involvement from the beginning of research. In fact, we have conducted DR joint research with more than 10 academia. Furthermore, we are also promoting our China business by supporting the deployment of excellent Japanese pharmaceuticals and medical technologies to China, and conversely, the deployment of excellent Chinese pharmaceuticals and medical technologies to Japan. In addition to pharmaceuticals, we also focus on the creation of new businesses such as health foods.
We are deeply grateful to our shareholders, government, universities, medical institutions, other companies, and other related organizations, as well as our employees, who have made it possible for us to continue our business for so long. In response to this gratitude, we will continue to strive for further development. We look forward to your continued support and cooperation.
Chairman, President and CEO, Ph. D.
Tohru Mizushima
